Navigation Links
ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
Date:3/4/2008

IRVINE, Calif., March 4 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will release fourth quarter 2007 financial results on March 6, 2008, after the U.S. markets close. ISTA will host a conference call, with a simultaneous webcast, to discuss these results and provide a commercial and pipeline update at 5:00 p.m. Eastern Time on March 6.

To access the live conference call, U.S. and Canadian participants may dial 866-831-6270; international participants may dial 617-213-8858. The access code for the live call is 99457780. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 57762235. This conference call also will be webcast live and archived on ISTA's website until April 7, 2008, at http://www.istavision.com.

About ISTA

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
2. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
7. Lotus Pharmaceuticals Raises $5 Million in Private Placement
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
10. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
11. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 03, 2015 , ... ... and frequently listed among the most influential leaders in healthcare, will offer the ... Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at the ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system ... complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or ... of any given guide RNA (sgRNA or crRNA) to create a break in the ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
... , , , ANNAPOLIS, ... PIP ), a biodefense company developing medical countermeasures against biological ... agreements for the issuance of 2-year, 10% unsecured senior convertible ... private placement of approximately $19.3 million. , , ...
... July 27 Health Robotics today announced,that it has ... to market,implement, and support its I.V. Workflow Engine and ... North America. One of,its software modules (OncoCube) has already ... University of Colorado Hospital [Denver], in,addition to all-digital ...
... , , , ... reveals that adults living in the country,s fifth largest city are ... and complex conditions. Many commonly used therapy classes including drugs to ... have experienced increases in adults 20 and older. , ...
... , Trinitas Comprehensive Cancer Center in Elizabeth, ... chemotherapy program in place , , LOS ... a variety of cancers--along with projections from the National Comprehensive Cancer Network ... by 2013--raise questions for both clinicians and patients with regard to the ...
... COLD SPRING HARBOR, N.Y., July 27 AccuVein LLC, ... illumination device, today announced that its quality system has received ... to customers around the globe AccuVein,s commitment to the quality ... and delivery procedures. , , ...
... , FRANKLIN, Mass., July 27 PLC ... innovative cardiac and vascular medical device-based technologies, today announced it ... capabilities provided by RenalGuard(R) from the Canadian Intellectual Property Office ... patent for RenalGuard in Canada. , , ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2
(Date:9/2/2015)... 2015  Research and Markets ( http://www.researchandmarkets.com/research/rf2c5p/an_introduction ) ... Introduction to the Medical Devices Directive (London, UK ... offering. This seminar provides a ... It will explain the Directives and which products ... to choose one and outline what a manufacturer ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Markets, and Companies" to their offering. ... a multi-disciplinary clinical specialty, aimed at improving patient ... to individually adjust the dose of drugs for ...
(Date:9/2/2015)... Sept. 2, 2015  Boca Raton Regional Hospital,s ... begun performing ultra-minimally invasive left atrial appendage ligation ... such as Coumadin, Xarelto or Effient. Dr. Cartledge, ... Hospital, is one of a select group of ... two microscopic incisions in order to seal off ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... Sanofi (EURONEXT: SAN and NYSE: ... its dermatology business, Dermik, to Valeant Pharmaceuticals International ... consideration of US $425 million. Valeant is a ... therapeutic areas, based in Mississauga, Ontario, Canada. ...
... Reportlinker.com announces that a new market ... Maximizing Pharmaceutical Licensing Opportunities ... Introduction The ... licensing, examining deal volumes, values and structure. ...
Cached Medicine Technology:Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. 2Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. 3Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. 4Maximizing Pharmaceutical Licensing Opportunities 2Maximizing Pharmaceutical Licensing Opportunities 3Maximizing Pharmaceutical Licensing Opportunities 4
RCB™ Rotator Cuff Buttress is a completely resorbable plate that will alleviate suture migration in open or mini-Open rotator cuff repairs....
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... an absorbable co-polymer synthesized from all-natural ... glycolic acid. Unlike the homopolymers in ... acid (PLLA) or 100% poly-glycolic acid ... (without crystallinity), meaning that its degradation ...
... Medicine™ AnchorSew™ 3 mm is a resorbable repair ... Medicine ArthroSew suturing device to attach soft tissue ... implanted into a prepared hole in the bone, ... soft tissue anchors are made of a resorbable ...
Medicine Products: